Evolutionary model of brain tumor circulating cells: Cellular galaxy

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Diagnostics

Background:

• Circulating tumor cells (CTCs) are crucial in cancer progression, yet a categorized diagnostic strategy is lacking.
• Understanding CTC heterogeneity and protein expression is key to deciphering brain tumor evolution.
• Personalized management requires a detailed analysis of CTC behavior in tumor and blood.

Purpose of the Study:

• To investigate circulating tumor cells (CTCs) in brain tumors and blood.
• To assay protein expression (PE) intensity in CTCs for personalized insights.
• To correlate CTC protein expression with tumor characteristics and evolution.

Main Methods:

• Analyzed protein expression (PE) in tumor cells and CTCs from 18 brain tumor patients (meningioma and metastatic).
• Utilized immunofluorescence and a ratio test (T/CTC) to classify PE of specific markers (CCL2, VEGF, EGF, CD133, cyclin E, neurofilament marker, cytokeratin 19, CD45).
• Examined histopathologic characteristics and specific genetic polymorphisms.

Main Results:

• Elevated PE in CTCs correlated with tumor evolution and metastatic events, suggesting prognostic value.
• Diverse PE in CTCs indicated tumor evolution; co-expression of CCL2/EGF and CCL2/VEGF facilitated tumor progression.
• Specific protein expression patterns in CTCs (e.g., neurofilament marker/CD133/VEGF in meningioma; cytokeratin 19/CD45/cyclin E in metastatic tumors) clarified tumor biology.

Conclusions:

• Tumor evolution mechanisms involve diverse protein expression models in CTCs.
• Co-expression of specific proteins (CCL2/EGF/VEGF, NM/CD133/VEGF) in CTCs may indicate invasiveness.
• The cytokeratin-19+/CD45- profile in CTCs can be a marker for metastatic brain tumors.